AR061842A1 - Pirimidil ciclopentanos hidroxilados y metoxilados como inhibidores de la proteina quinasa akt - Google Patents

Pirimidil ciclopentanos hidroxilados y metoxilados como inhibidores de la proteina quinasa akt

Info

Publication number
AR061842A1
AR061842A1 ARP070103033A ARP070103033A AR061842A1 AR 061842 A1 AR061842 A1 AR 061842A1 AR P070103033 A ARP070103033 A AR P070103033A AR P070103033 A ARP070103033 A AR P070103033A AR 061842 A1 AR061842 A1 AR 061842A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
phenyl
cycloalkyl
attached form
Prior art date
Application number
ARP070103033A
Other languages
English (en)
Spanish (es)
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061842(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of AR061842A1 publication Critical patent/AR061842A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
ARP070103033A 2006-07-06 2007-07-06 Pirimidil ciclopentanos hidroxilados y metoxilados como inhibidores de la proteina quinasa akt AR061842A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81871806P 2006-07-06 2006-07-06

Publications (1)

Publication Number Publication Date
AR061842A1 true AR061842A1 (es) 2008-09-24

Family

ID=38686743

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP070103033A AR061842A1 (es) 2006-07-06 2007-07-06 Pirimidil ciclopentanos hidroxilados y metoxilados como inhibidores de la proteina quinasa akt
ARP130104510A AR093810A2 (es) 2006-07-06 2013-12-05 Pirimidil ciclopentanos hidroxilados y metoxilados como inhibidores de la proteina quinasa ak, sus usos, composiciones, kits y formas de dosificacion
ARP170102366A AR109424A2 (es) 2006-07-06 2017-08-25 Pirimidil ciclopentanos hidroxilados y metoxilados como inhibidores de la proteína quinasa akt

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP130104510A AR093810A2 (es) 2006-07-06 2013-12-05 Pirimidil ciclopentanos hidroxilados y metoxilados como inhibidores de la proteina quinasa ak, sus usos, composiciones, kits y formas de dosificacion
ARP170102366A AR109424A2 (es) 2006-07-06 2017-08-25 Pirimidil ciclopentanos hidroxilados y metoxilados como inhibidores de la proteína quinasa akt

Country Status (34)

Country Link
EP (4) EP2402325B1 (instruction)
JP (4) JP5266216B2 (instruction)
KR (5) KR20140093291A (instruction)
CN (2) CN102816124A (instruction)
AR (3) AR061842A1 (instruction)
AT (1) ATE524447T1 (instruction)
AU (1) AU2007269060B2 (instruction)
BR (3) BRPI0713923B8 (instruction)
CA (2) CA2836316A1 (instruction)
CL (1) CL2007001993A1 (instruction)
CO (1) CO6150161A2 (instruction)
CR (1) CR10600A (instruction)
CY (1) CY1112117T1 (instruction)
DK (2) DK2402325T3 (instruction)
ES (3) ES2372774T3 (instruction)
HR (1) HRP20110908T1 (instruction)
HU (1) HUE026237T2 (instruction)
IL (2) IL196028A (instruction)
IN (1) IN2014KN02886A (instruction)
MA (1) MA31655B1 (instruction)
MX (4) MX377920B (instruction)
MY (1) MY147364A (instruction)
NO (1) NO342346B1 (instruction)
NZ (3) NZ597647A (instruction)
PL (2) PL2049501T3 (instruction)
PT (1) PT2049501E (instruction)
RS (1) RS52212B (instruction)
RU (2) RU2478632C2 (instruction)
SG (4) SG188905A1 (instruction)
SI (2) SI2049501T1 (instruction)
TW (2) TWI402266B (instruction)
UA (1) UA95641C2 (instruction)
WO (1) WO2008006040A1 (instruction)
ZA (1) ZA200900070B (instruction)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN101516891B (zh) * 2006-07-06 2013-06-05 阵列生物制药公司 作为akt蛋白激酶抑制剂的二氢噻吩并嘧啶
CN103288753A (zh) 2006-07-06 2013-09-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的环戊二烯并[d]嘧啶
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US20110135569A1 (en) 2007-03-20 2011-06-09 Peak Biosciences Inc. Method for therapeutic administration of radionucleosides
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
KR101624361B1 (ko) 2007-07-05 2016-05-25 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CA2692502C (en) 2007-07-05 2016-03-01 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
EP2250155B1 (en) * 2008-01-09 2013-07-03 Array Biopharma, Inc. 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
RU2504542C2 (ru) 2008-01-09 2014-01-20 Эррэй Биофарма Инк. Гидроксилированные пиримидилциклопентаны в качестве ингибиторов протеинкиназы (акт)
CN102015708B (zh) 2008-01-09 2014-03-26 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
ES2401685T3 (es) * 2008-01-09 2013-04-23 Array Biopharma, Inc. Pirimidil ciclopentano hidroxilado como inhibidor de la proteína quinasa AKT
KR20130132956A (ko) * 2010-12-23 2013-12-05 제넨테크, 인크. 신생물의 치료를 위한 자식증 유도자 및 억제제 조합 요법
EP3617330B1 (en) * 2011-04-01 2023-12-27 Genentech, Inc. Biomarkers for predicting sensitivity to cancer treatments
MY179607A (en) 2011-04-01 2020-11-11 Genentech Inc Combinations of akt inhibitor compounds and abiraterone, and methods of use
JP6147246B2 (ja) 2011-04-01 2017-06-14 ジェネンテック， インコーポレイテッド Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
CA2873658C (en) * 2012-05-17 2021-01-26 Genentech, Inc. Process for making amino acid compounds
KR102125588B1 (ko) * 2012-05-17 2020-06-22 제넨테크, 인크. 무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법
BR112014028570A2 (pt) * 2012-05-17 2018-04-24 Array Biopharma Inc processo para fabricação de compostos de ciclopentilpirimidina hidroxilada.
WO2013173768A1 (en) 2012-05-17 2013-11-21 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
AU2013262521B2 (en) 2012-05-17 2017-03-02 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
JP2016502974A (ja) * 2012-12-07 2016-02-01 ザ ジェネラル ホスピタル コーポレイション Ｐｉ３ｋ／ａｋｔ阻害剤化合物とｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び高増殖性疾患の治療におけるその使用
JP6340162B2 (ja) * 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
SG10201901578UA (en) 2013-11-15 2019-03-28 Hoffmann La Roche Processes for the preparation of pyrimidinylcyclopentane compounds
MA51165A (fr) * 2014-09-26 2020-10-21 Hoffmann La Roche Procédés de préparation de composés de (cyclopentyl[d]pyrimidin-4-yl)pipérazine
EP3496722B1 (en) 2016-08-10 2025-07-16 F. Hoffmann-La Roche AG Pharmaceutical compositions comprising akt protein kinase inhibitors
CA3041840A1 (en) 2016-10-28 2018-05-03 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating ezh2-mediated cancer
US11472799B2 (en) * 2018-03-06 2022-10-18 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
US12110295B2 (en) 2018-06-21 2024-10-08 Icahn School Of Medicine At Mount Sinai WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds and methods of use
US11701356B2 (en) 2018-12-19 2023-07-18 Genentech, Inc. Treatment of breast cancer using combination therapies comprising an AKT inhibitor, a taxane, and a PD-L1 inhibitor
AU2019407426A1 (en) 2018-12-21 2021-07-22 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN117964620A (zh) 2019-01-29 2024-05-03 南京正大天晴制药有限公司 Akt抑制剂
US20220249511A1 (en) 2019-03-29 2022-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
JP7667742B2 (ja) * 2019-04-09 2025-04-23 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド Ａｔｐ競合性ａｋｔ阻害剤ｇｄｃ－００６８とｅ３リガーゼリガンドとの結合によるａｋｔの分解および使用方法
CA3167999A1 (en) * 2020-03-17 2021-09-23 Xin Li Fused bicyclic derivative, preparation method therefor, and pharmaceutical use thereof
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
WO2021254920A1 (en) 2020-06-16 2021-12-23 F. Hoffmann-La Roche Ag Process for making hydroxylated cyclopentylpyrimidine compounds
WO2022017449A1 (zh) 2020-07-22 2022-01-27 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途
TWI750905B (zh) * 2020-11-19 2021-12-21 財團法人國家衛生研究院 噻唑化合物作為蛋白質激酶抑制劑
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
WO2023043869A1 (en) * 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Solid state forms of ipatasertib citrate
CN113788834B (zh) * 2021-09-18 2022-11-29 河南奥思恩医药科技有限公司 2,4-二氯-6,7-二氢-5H-吡咯并[3,4-d]嘧啶盐酸盐的制备方法
WO2023109540A1 (zh) * 2021-12-17 2023-06-22 中国医药研究开发中心有限公司 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途
JP2025510910A (ja) 2022-03-31 2025-04-15 アストラゼネカ・アクチエボラーグ 癌の処置のための、ａｋｔ阻害剤との組み合わせにおける上皮成長因子受容体（ｅｇｆｒ）チロシンキナーゼ阻害剤
AU2023362285A1 (en) 2022-10-17 2025-05-29 Astrazeneca Ab Combinations of a serd for the treatment of cancer
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
CN120712346A (zh) 2023-01-31 2025-09-26 豪夫迈·罗氏有限公司 具有增加的酮还原酶活性的突变型酮还原酶以及涉及其的方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NL7112938A (instruction) * 1970-09-30 1972-04-05
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JP3297058B2 (ja) * 1997-01-08 2002-07-02 エフ．ホフマン−ラ ロシュ アーゲー 三環式ベンゾ［ｅ］イソインドール及びベンゾ［ｈ］イソキノリン
ES2152902B1 (es) * 1999-07-27 2001-08-16 Medichem Sa Procedimiento de obtencion de venlafaxina
IL154514A0 (en) * 2000-08-18 2003-09-17 Millennium Pharm Inc Quinazoline derivatives and pharmaceutical compositions containing the same
AU2001290914A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2365905T3 (es) * 2001-03-30 2011-10-13 King Pharmaceuticals, Inc. Compuestos de tiofeno condensados y uso de los mismos en el tratamiento del dolor crónico.
ATE424388T1 (de) * 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
MXPA04007191A (es) * 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
NZ590160A (en) * 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
EP1751133B1 (en) * 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2005113762A1 (en) 2004-05-18 2005-12-01 Pfizer Products Inc. CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
EP1866822A4 (en) * 2005-03-03 2010-09-01 Burnham Inst Medical Research SCREENING PROCEDURE FOR PROTEIN KINASE B INHIBITORS USING VIRTUAL DOCKING APPARATUS AND COMPOSITIONS AND COMPOSITIONS DISCOVERED THEREFOR
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
CN103288753A (zh) * 2006-07-06 2013-09-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的环戊二烯并[d]嘧啶
CN101516891B (zh) * 2006-07-06 2013-06-05 阵列生物制药公司 作为akt蛋白激酶抑制剂的二氢噻吩并嘧啶

Also Published As

Publication number Publication date
UA95641C2 (xx) 2011-08-25
CL2007001993A1 (es) 2008-06-20
HK1160638A1 (en) 2012-08-10
BRPI0713923B8 (pt) 2021-05-25
JP2013091670A (ja) 2013-05-16
KR20130141717A (ko) 2013-12-26
MX2019008117A (es) 2019-09-04
CA2656622C (en) 2017-09-12
SI2049501T1 (sl) 2012-01-31
KR20090030333A (ko) 2009-03-24
SG184706A1 (en) 2012-10-30
KR101578877B1 (ko) 2016-02-22
NZ573732A (en) 2012-03-30
KR20140093291A (ko) 2014-07-25
RU2012155606A (ru) 2014-06-27
IL196028A0 (en) 2009-09-01
EP2399909B1 (en) 2015-08-26
CN101578273A (zh) 2009-11-11
HK1126768A1 (en) 2009-09-11
BR122013028005B8 (pt) 2021-05-25
SG10201802127UA (en) 2018-04-27
EP2049501B1 (en) 2011-09-14
IL241705A0 (en) 2015-11-30
AU2007269060A1 (en) 2008-01-10
TW200817373A (en) 2008-04-16
CN101578273B (zh) 2012-11-14
MA31655B1 (fr) 2010-09-01
NO342346B1 (no) 2018-05-07
NZ610633A (en) 2014-12-24
AR109424A2 (es) 2018-11-28
NO20090581L (no) 2009-04-06
AU2007269060B2 (en) 2014-02-20
HK1160134A1 (en) 2012-08-10
DK2049501T3 (da) 2011-12-12
KR20150051240A (ko) 2015-05-11
SG185980A1 (en) 2012-12-28
PL2402325T3 (pl) 2016-01-29
KR101178672B1 (ko) 2012-09-07
TW201332994A (zh) 2013-08-16
BRPI0713923B1 (pt) 2020-09-29
MX377920B (es) 2025-03-11
HUE026237T2 (en) 2016-06-28
KR20130029364A (ko) 2013-03-22
EP2966065A3 (en) 2016-03-02
CY1112117T1 (el) 2015-11-04
JP5836294B2 (ja) 2015-12-24
RU2009103900A (ru) 2010-08-20
JP2013177470A (ja) 2013-09-09
HRP20110908T1 (hr) 2012-02-29
PT2049501E (pt) 2011-12-30
JP2014231530A (ja) 2014-12-11
SI2402325T1 (sl) 2015-12-31
ZA200900070B (en) 2010-03-31
BRPI0713923A2 (pt) 2013-07-02
MX2008016202A (es) 2009-02-11
RU2478632C2 (ru) 2013-04-10
EP2402325B1 (en) 2015-08-26
MX366319B (es) 2019-07-05
CR10600A (es) 2009-02-20
BR122013028012B8 (pt) 2021-05-25
CA2656622A1 (en) 2008-01-10
ES2554228T3 (es) 2015-12-17
CO6150161A2 (es) 2010-04-20
BR122013028012B1 (pt) 2021-04-06
PL2049501T3 (pl) 2012-02-29
CA2836316A1 (en) 2008-01-10
IN2014KN02886A (instruction) 2015-05-08
MX337843B (es) 2016-03-22
NZ597647A (en) 2013-08-30
BR122013028005B1 (pt) 2021-04-06
MY147364A (en) 2012-11-30
EP2402325A3 (en) 2012-06-13
ATE524447T1 (de) 2011-09-15
EP2399909A1 (en) 2011-12-28
ES2372774T3 (es) 2012-01-26
JP5266216B2 (ja) 2013-08-21
KR101495408B1 (ko) 2015-02-25
EP2402325A2 (en) 2012-01-04
AR093810A2 (es) 2015-06-24
JP2009542723A (ja) 2009-12-03
TWI402266B (zh) 2013-07-21
RS52212B (en) 2012-10-31
EP2049501A1 (en) 2009-04-22
WO2008006040A1 (en) 2008-01-10
SG188905A1 (en) 2013-04-30
EP2966065A2 (en) 2016-01-13
DK2402325T3 (en) 2015-12-07
ES2554252T3 (es) 2015-12-17
IL196028A (en) 2017-02-28
CN102816124A (zh) 2012-12-12

Similar Documents

Publication Publication Date Title
AR061842A1 (es) Pirimidil ciclopentanos hidroxilados y metoxilados como inhibidores de la proteina quinasa akt
AR061844A1 (es) Pirimidil-ciclopentanos como inhibidores de protein-quinasa akt
AR070136A1 (es) Pirimidil ciclopentanos como inhibidores de la akt proteina quinasa
ES2528451T3 (es) Inhibidores de esfingosina cinasa
ES2515194T3 (es) Derivados de pirrolidina
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
AR081577A1 (es) Derivados de aminopirimidina como moduladores de la lrrk2
AR081932A1 (es) Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes
AR046080A1 (es) Piridinonas sustituidas
CY1118879T1 (el) Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
AR054529A1 (es) Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
AR063601A1 (es) Arilamidas sustituidas por tiazol u oxazol
AR097431A1 (es) Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR043837A1 (es) Pirazoles sustituidos
CR20190261A (es) Inhibidores de la tirosina quinasa de bruton
AR083798A1 (es) Inhibidores selectivos de glucosidasas y sus usos
AR046085A1 (es) Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico
UY29749A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, así como su uso como medicamentos
AR109991A1 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
AR109990A1 (es) Derivados de imidazopirazinonas inhibidores de pde1
AR055666A1 (es) Inhibidores inntr

Legal Events

Date Code Title Description
FC Refusal